Trial · NCT03457701
Results by group106
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 106
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | Daprodustat | Period 1, DAY 28 | 3.0 | Standard Deviation 18.13 | Percentage (%) of transferrin saturation |
| Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | rhEPO | Period 1, DAY 28 | 8.2 | Standard Deviation 14.41 | Percentage (%) of transferrin saturation |
| Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | Daprodustat | Period 2, DAY 14 | -5.5 | Standard Deviation 13.40 | Percentage (%) of transferrin saturation |
| Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | rhEPO | Period 2, DAY 14 | -4.8 | Standard Deviation 10.98 | Percentage (%) of transferrin saturation |
| Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | Daprodustat | Period 2, DAY 28 | -6.7 | Standard Deviation 14.57 | Percentage (%) of transferrin saturation |
| Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | rhEPO | Period 2, DAY 28 | -4.7 | Standard Deviation 11.29 | Percentage (%) of transferrin saturation |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | Daprodustat | Period 1, DAY 14 | -0.218 | Standard Deviation 0.1736 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | rhEPO | Period 1, DAY 14 | 0.063 | Standard Deviation 0.1669 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | Daprodustat | Period 1, DAY 28 | -0.340 | Standard Deviation 0.2665 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | rhEPO | Period 1, DAY 28 | -0.015 | Standard Deviation 0.1598 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | Daprodustat | Period 2, DAY 14 | -0.338 | Standard Deviation 0.2978 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | rhEPO | Period 2, DAY 14 | 0.227 | Standard Deviation 0.1086 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | Daprodustat | Period 2, DAY 28 | -0.308 | Standard Deviation 0.3180 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | rhEPO | Period 2, DAY 28 | 0.195 | Standard Deviation 0.2239 | Milligrams per liter (mg/L) |
| Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | Daprodustat | Period 1, DAY 14 | 1.126 | Geometric Coefficient of Variation 20.1853 | Microgram per liter (ug/L) |
| Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | rhEPO | Period 1, DAY 14 | 0.937 | Geometric Coefficient of Variation 16.2891 | Microgram per liter (ug/L) |
| Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | Daprodustat | Period 1, DAY 28 | 1.109 | Geometric Coefficient of Variation 24.7052 | Microgram per liter (ug/L) |
| Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | rhEPO | Period 1, DAY 28 | 1.004 | Geometric Coefficient of Variation 5.4818 | Microgram per liter (ug/L) |
| Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | Daprodustat | Period 2, DAY 14 | 1.067 | Geometric Coefficient of Variation 32.7697 | Microgram per liter (ug/L) |
| Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | rhEPO | Period 2, DAY 14 | 0.957 | Geometric Coefficient of Variation 20.2623 | Microgram per liter (ug/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03457701/results?page=2